Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Active-controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients With Stage 2 Systolic Hypertension

NCT00760266 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00760266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00760266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Active-controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients With Stage 2 Systolic Hypertension
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2008
Completion date
April 30, 2009
Enrollment
451 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension